What was the primary driver of the significant increase in Pfizer's revenues in the third quarter and first nine months of 2003?

The primary driver was the acquisition of Pharmacia Corporation on April 16, 2003, which contributed Pharmacia's results of operations to Pfizer's consolidated financial statements from the acquisition date onwards.

How did the acquisition of Pharmacia impact Pfizer's balance sheet?

The acquisition led to a substantial increase in assets, including the recognition of approximately $21.7 billion in goodwill and $34.5 billion in identifiable intangible assets, reflecting the fair value of Pharmacia's assets and liabilities at the time of acquisition.

What were the major non-recurring items impacting Pfizer's financial results during this period?

The most significant non-recurring items were the merger-related costs and a substantial charge of $5.043 billion for in-process research and development related to the Pharmacia acquisition. Additionally, there were significant purchase accounting adjustments, including the write-up of inventory to fair value and amortization of newly recognized intangible assets.

What is the significance of the 'Adjusted Income' presented in the MD&A section?

Adjusted income is a non-GAAP measure that excludes certain significant items, such as purchase accounting adjustments (IPR&D charge, inventory write-up, intangible amortization), merger-related costs, and gains/losses from divestitures. Pfizer uses this measure to provide a view of its ongoing operational performance, excluding the impacts of the Pharmacia acquisition and other non-recurring events.

PFE 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported strong revenue growth in the third quarter and first nine months of 2003, primarily driven by the significant acquisition of Pharmacia Corporation in April 2003. This acquisition, valued at approximately $56 billion, has substantially reshaped Pfizer's financial statements, leading to increased revenues, costs, and assets, including substantial goodwill and intangible assets. Despite the integration costs and the significant impact of purchase accounting adjustments, Pfizer's core pharmaceutical business demonstrated robust performance, with key products like Lipitor and Norvasc showing continued growth. The company also reported significant proceeds from the divestiture of non-core businesses, such as the Adams confectionery and Schick-Wilkinson Sword shaving products, which contributed positively to cash flow and allowed for strategic realignment. The report highlights ongoing investments in research and development, with a significant pipeline of new drug applications and clinical trials, underscoring Pfizer's commitment to future growth through innovation.

Key Highlights

1Acquisition of Pharmacia Corporation for approximately $56 billion significantly impacted revenues and balance sheet items, creating substantial goodwill and intangible assets.
2Total revenues increased by 56% in Q3 2003 and 35% in the first nine months of 2003 compared to the prior year, largely due to the inclusion of Pharmacia's results.
3Significant proceeds were generated from the sale of discontinued operations, including the Adams confectionery and Schick-Wilkinson Sword businesses, contributing to cash flow and strategic repositioning.
4Despite integration costs and purchase accounting adjustments, core pharmaceutical products like Lipitor and Norvasc showed continued strong performance.
5Research and development expenses increased by 51% in Q3 and 31% in the first nine months, reflecting continued investment in pipeline development and the integration of Pharmacia's R&D.
6The company reported substantial merger-related costs and a significant in-process research and development charge of $5.043 billion related to the Pharmacia acquisition.
7Shareholders' equity per common share saw a significant increase, primarily due to the Pharmacia acquisition.

PFIZER INC Quarterly Report for Q3 Ended Sep 28, 2003

Summary

Key Highlights

Frequently Asked Questions